Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice.
about
Therapeutic strategies for the clinical blockade of IL-6/gp130 signalingPreclinical validation of interleukin 6 as a therapeutic target in multiple myelomaIL-6 and MYC collaborate in plasma cell tumor formation in mice.Activated Natural Killer Cells Mediate the Suppressive Effect of Interleukin-4 on Tumor Development via STAT6 Activation in an Atopic Condition Melanoma Model.IL-6 transgenic mouse model for extraosseous plasmacytoma.Distinct granuloma responses in C57BL/6J and BALB/cByJ mice in response to pristane.Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice.The class-specific BCR tonic signal modulates lymphomagenesis in a c-myc deregulation transgenic model.The tumor microenvironment is the main source of IL-6 for plasma cell tumor development in miceImmunopathogenesis of environmentally induced lupus in mice.Constitutive NF-kappaB activation confers interleukin 6 (IL6) independence and resistance to dexamethasone and Janus kinase inhibitor INCB018424 in murine plasmacytoma cells.Survival and proliferation factors of normal and malignant plasma cells.IL-6 Contributes to the Defective Osteogenesis of Bone Marrow Stromal Cells from the Vertebral Body of the Glucocorticoid-Induced Osteoporotic Mouse.Increased NHC Cells in the Peritoneal Cavity of Plasmacytoma Susceptible BALB/c Mouse.Interleukin 6 is required for the development of collagen-induced arthritisInterleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus.Kaposi's Sarcoma-Associated Herpesvirus Latency Locus Compensates for Interleukin-6 in Initial B Cell Activation.Lutzomyia longipalpis salivary peptide maxadilan alters murine dendritic cell expression of CD80/86, CCR7, and cytokine secretion and reprograms dendritic cell-mediated cytokine release from cultures containing allogeneic T cellsWaldenström macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse modelsInterleukin-6 receptor specific RNA aptamers for cargo delivery into target cells.INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell supportInterleukin-6 production and secretion by human parathyroids.IL-6 blocks a discrete early step in lymphopoiesis.Role of interleukin-6 in the pathogenesis of murine plasmacytoma and human multiple myeloma.Mouse models of multiple myeloma: technologic platforms and perspectives.Targeted IgA Fc receptor I (FcαRI) therapy in the early intervention and treatment of pristane-induced lupus nephritis in mice.
P2860
Q27002391-5F26507D-B234-4621-886D-C46355910AA5Q27027729-EC40D228-3688-408F-924B-8DD72A423B51Q33706389-758165D9-3711-4119-9916-148007F65F4DQ33765161-E5215E10-72C2-47C3-8CEA-C47428999A73Q34009997-712ED563-A7E5-4791-89B2-9745A01338F4Q34284178-B883EC7D-D068-43DE-964B-94B227AE95D9Q34380431-660EE030-41BD-454B-B04D-0858C428682FQ34619195-6A5EA36C-F192-49A5-BEA5-4A1C61244011Q34861202-AABCA8C1-97AE-4645-84AD-69B40BDACF59Q35029474-7B0615E7-6905-486A-A061-1A25733E7613Q35150054-C46CBA5E-BCAD-4F86-AA10-DAEDD1208C54Q35211028-A82A8CA6-6D3D-45FC-992D-BEC0801CB915Q36003384-39428CA5-2A6D-4622-B6B6-1663DC7D3980Q36173295-1524B4EF-69DD-4E8B-B0C3-DCF0BA985C29Q36400353-42A5781F-51DF-4E03-886D-6F162287524EQ36404163-98C474DD-1B54-4235-B439-1D05BC0D0689Q36524036-17B6B313-5464-450B-8EC3-AF3DAE16F4D1Q36712427-A738DDBA-5C1C-4AA0-94A6-8A776D64691AQ38150849-ED9EDDB8-FD0B-45F1-A746-85EBBBD0AF19Q38328537-6FFBDE7F-B4EE-4B6A-87C6-803430FD1A7FQ39752237-92BFCE17-8645-4F97-B3A1-01AC2068F23CQ40576893-A8EBE672-3EA9-431D-9CA0-86CDC608AF5DQ42194383-26A2EADE-9B9B-429F-99CF-167EE890C4D6Q42840168-50C5F8D0-223D-4E28-9FD3-F1DC3B15D255Q55038802-4EE866D0-F5FA-41F0-9056-A31944C67B9FQ55059074-2CCABB6F-E541-438B-B7F2-51144202D8AA
P2860
Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Defective development of prist ...... eukin-6-deficient BALB/c mice.
@ast
Defective development of prist ...... eukin-6-deficient BALB/c mice.
@en
type
label
Defective development of prist ...... eukin-6-deficient BALB/c mice.
@ast
Defective development of prist ...... eukin-6-deficient BALB/c mice.
@en
prefLabel
Defective development of prist ...... eukin-6-deficient BALB/c mice.
@ast
Defective development of prist ...... eukin-6-deficient BALB/c mice.
@en
P2093
P2860
P1476
Defective development of prist ...... leukin-6-deficient BALB/c mice
@en
P2093
Aquilina M
Cappelletti M
Lattanzio G
P2860
P304
P407
P577
1997-09-01T00:00:00Z